Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. - Wikidata - wikimedia - TriplyDB

Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.

Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.

http://www.wikidata.org/entity/Q35605560

about

Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications Clinical Predictive Factors in Diabetic Kidney Disease Progression Stop chronic kidney disease progression: Time is approaching The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy Risk factors for renal impairment revealed after unilateral adrenalectomy in patients with primary aldosteronism.Effects of topiroxostat in hyperuricemic patients with chronic kidney disease.The NLRP3 inflammasome in kidney disease and autoimmunity.Management of Gout and Hyperuricemia in CKD.Time to target uric acid to retard CKD progression.Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis.Diabetic nephropathy: Time to withhold development and progression - A review.Prevalence of chronic kidney disease and its association with cardio-metabolic risk factors in the adult Romanian population: the PREDATORR study.Treatment of asymptomatic hyperuricemia in chronic kidney disease: A new target in an old enemy - A review.Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial.Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis.Podocyte Injury and Albuminuria in Experimental Hyperuricemic Model Rats.The grey zone of Hyperuricemia in chronic kidney disease.Gout: will the "King of Diseases" be the first rheumatic disease to be cured?Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis.Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor.Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis.Augmented Association Between Blood Pressure and Proteinuria in Hyperuricemic Patients with Non-Nephrotic Chronic Kidney Disease.The problem of cardio-renal diseases in patients with gout.Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.Cardiac and renal protective effects of urate-lowering therapy.The challenge of Mendelian randomization approach.Uric acid predicts adverse outcomes in chronic kidney disease: a novel insight from trajectory analyses.Physiology of Hyperuricemia and Urate-Lowering Treatments.Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis.Association between post-transplant uric acid level and renal allograft fibrosis: Analysis using Banff pathologic scores from renal biopsies

P2860

Q26738948-D8D60B0A-DDF1-4F24-91F8-7159587B9573 Q26749494-BD8D30AD-6CBF-46BF-B545-E905351392F5 Q28078020-621527B2-DCD3-417D-A25F-0575CEA3A737 Q35914820-D7384E71-32ED-46F5-AAA9-4267650D2061 Q36373688-E16FDD8C-012B-4036-A2DB-A7D875673482 Q37327876-5611A966-55CC-4FE4-A857-68068ED2ECD0 Q38656095-51BE911A-3A9A-4F04-B37F-B5F2E4901CF0 Q38787339-D390C3AB-6E96-4EE4-9165-342A0819909C Q38812962-E37D2311-27F3-4CA8-8B2B-21479F544143 Q38848997-761D7B84-D60E-4282-9805-0695853DD2F2 Q38968869-01135830-793D-41A1-B105-6C0B9791456D Q39327680-76BA2E78-96D5-491B-BADD-9EBCF5C92633 Q40532134-F87CC2A5-88AC-4018-BF5A-ABC30CCD48C8 Q41026351-A59118FE-77F6-48E8-AC37-44CD7FB9D3E0 Q41026359-3AC27201-48A7-4855-9D95-65B2B5C488CF Q41386932-03BBCABF-522C-458E-A21D-621884F299B5 Q42316455-81A1C05E-150C-4138-AF3D-7C10B90DCBF0 Q42333924-393BC558-4ED2-402A-9189-9DB7DE2A70D4 Q42370099-E4DE7627-CBE5-4F03-8C38-8B0D0D55395A Q47138528-4BD0C703-7F8D-40CE-A05F-0FD20A86A592 Q47150749-E082B5F6-18B6-4BC8-AF36-636FC8A2C272 Q47169238-A1234E10-ECFE-4E6E-9350-519CDC4381D8 Q47777655-4769A3D8-901A-460B-BEBC-8BE20E600956 Q47914665-6F92F920-8577-4BA8-85BF-49ADD3AAF575 Q49584618-B3042307-0E45-44A3-A98B-09A4CFFB6E77 Q49616077-9753B66F-29C4-4441-9A88-5E5D19DC5071 Q49793158-B0B57DDB-5584-4E38-A5C3-BB6D529815C4 Q50000165-1194D1FB-385D-48A6-AA74-B9453650F1FA Q55163806-BDF9896A-9409-49F7-9488-C4D67B1D8C3F Q55412646-CA9552B5-4A87-4B47-8F2F-FBA31C76A411 Q58803566-DFD3C513-A1C5-45F7-8ECC-98243A28D329

P2860

Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.

http://www.wikidata.org/entity/Q35605560

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Urate lowering therapy to impr ...... atic review and meta-analysis.

@ast

Urate lowering therapy to impr ...... atic review and meta-analysis.

@en

type

label

Urate lowering therapy to impr ...... atic review and meta-analysis.

@ast

Urate lowering therapy to impr ...... atic review and meta-analysis.

@en

prefLabel

Urate lowering therapy to impr ...... atic review and meta-analysis.

@ast

Urate lowering therapy to impr ...... atic review and meta-analysis.

@en

P1433

Q35605560-9C96219E-0F2B-473B-894F-E9B2287BA464

P1476

Q35605560-6A413B27-8547-4DFA-9CA4-D0849D4CCFA1

P2093

Q35605560-060B15C1-9380-4899-9151-7FA2D8494A7C

Q35605560-2D579EF2-E720-4020-A436-9BF636064B4A

Q35605560-9BDB5F95-19B0-457E-B538-00C372BF8DEA

Q35605560-CCE95443-9646-486E-B4CC-68B449738214

P275

Q35605560-20095F90-B978-45DE-8089-E93584181778

P2860

Q35605560-01639ED0-FB18-4193-A5E1-E3EE760DC54C

Q35605560-0A5A1784-062A-43B1-93EC-3CD550F6E865

Q35605560-1B255701-5E53-4D72-AD87-6F1F31F085FF

Q35605560-1C4135E7-CE8A-4BC7-9CB7-8417C1BDC323

Q35605560-259C231C-BA5F-43A0-B5B3-D6D77A4979CB

Q35605560-396FFBF5-1DAC-4188-B9E3-EFF9DAFAE388

Q35605560-4551175C-7441-4D06-9D51-5203C7AD92C8

Q35605560-45A51911-AE85-42D2-A295-C45F8CC61838

Q35605560-46CC1148-E786-4833-992D-F5DE99646484

Q35605560-491021EA-7CD7-4094-B4BB-0D1F4A6419D2

P304

Q35605560-39F1B2EC-545B-4601-BF06-90ABE4EC2368

P31

Q35605560-0B869690-567D-4AC7-899E-7E06D3B2BFDD

Q35605560-7560380c-3f6b-4538-a02b-9229327abc88

Q35605560-BFAF96BC-7689-4A52-89D6-EA2CE5BC6E27

P356

Q35605560-1CC64B67-2FE2-4972-8205-9028B782C258

P478

Q35605560-F453AC74-04E5-4A5F-A698-7E4E59D81EE9

P5008

Q35605560-8A9D7BED-97F2-4246-9E01-ABC85C0A4428

P577

Q35605560-56F1BB9F-C2AF-4D0D-9947-3676AE13F531

P5875

Q35605560-14EE1BB6-FFFC-45D1-A42C-255434DF31E4

P698

Q35605560-4C8EBDF8-521B-43E3-8D23-C1DF009231BD

P921

Q35605560-2B2ECCAA-7E6C-4499-9049-8B11EB1DE37D

Q35605560-E73C62EA-2289-4026-904E-751E280DCF6E

P932

Q35605560-2D720BE8-171D-4B91-BC62-938191C9185D

P356

S12882-015-0047-Z

P1433

P1476

Urate lowering therapy to impr ...... atic review and meta-analysis.

@en

P2093

Catherine M Clase

http://www.w3.org/2001/XMLSchema#string

Mandark Gandhi

http://www.w3.org/2001/XMLSchema#string

Robert Yang

http://www.w3.org/2001/XMLSchema#string

Tahir Kanji

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up

Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study.

Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: a meta-analysis.

Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease.

Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study.

Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function.

P304

58

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12882-015-0047-Z

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2015-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275666361

http://www.w3.org/2001/XMLSchema#string

P698

25928556

http://www.w3.org/2001/XMLSchema#string

P921

chronic kidney disease

P932

4431373

http://www.w3.org/2001/XMLSchema#string